# Role of Concentration in Opposing Effects of Anandamide on Nociceptive Synapses versus … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/role-of-concentration-in-opposing-effects-of-anandamide-on-nociceptive-synapses-versus/ > **Published:** 2026-08-07T12:23:26-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:01:52-04:00 > **Clinical Summary:** Anandamide dosing and pain response depend on concentration-dependent effects at nociceptive synapses, explaining paradoxical hyperalgesia in cannabis patients. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PainNeurologyResearchDosingSafetyMental HealthAnxiety Why This Matters This research clarifies how endocannabinoid concentration affects pain signaling differently at nociceptive versus non-nociceptive synapses, which could explain variable pain relief and [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) observed in cannabis patients. Understanding these concentration-dependent mechanisms may help clinicians optimize cannabinoid dosing to maximize analgesia while minimizing off-target effects on non-pain neural circuits. This molecular insight could inform development of more selective pain treatments and better patient counseling on dose titration for [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/). Clinical Summary This pharmacological study demonstrates that anandamide, an endogenous cannabinoid, produces opposing effects on pain-transmitting versus non-pain synapses depending on its concentration, with low concentrations enhancing nociceptive signaling while higher concentrations suppress it. The research reveals that these divergent effects arise from concentration-dependent activation of different cannabinoid receptor subtypes and downstream signaling pathways, suggesting that the therapeutic window for pain relief may be narrower than previously appreciated. These findings have important implications for cannabis-based [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/), as they indicate that subtherapeutic or variable cannabis concentrations might paradoxically worsen pain symptoms in some patients before achieving analgesic effects. Clinicians should be aware that inconsistent dosing or patient-to-patient variability in [cannabis metabolism](https://cedclinic.com/how-long-does-weed-stay-in-your-system/) could lead to unpredictable pain outcomes, potentially explaining why some patients report increased pain sensitivity following [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). This mechanistic understanding supports the need for standardized, concentration-controlled cannabis formulations and careful dose titration in [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) protocols rather than relying on variable plant material or inconsistent extracts. Dr. Caplan’s Take “This is in-vitro work exploring how endocannabinoid concentration might produce different effects on pain versus non-pain neural pathways, and the early signals here are worth watching—but we’re looking at isolated synapses in a dish, not the complexity of a living nervous system, so we need careful human studies before this translates into clinical guidance about [cannabis dosing](https://cedclinic.com/medical-cannabis-safety-facts/) or efficacy for pain.” Clinical Perspective 🧠 The endocannabinoid system’s concentration-dependent effects on pain signaling reveal important mechanistic complexity that complicates straightforward cannabinoid dosing for analgesia. This research demonstrates that anandamide and related endocannabinoids can have opposing effects at nociceptive versus non-nociceptive synapses depending on local concentrations, suggesting that simply increasing cannabinoid exposure may not reliably produce proportional analgesic benefit and could potentially interfere with beneficial pain signaling at certain doses. Clinicians should recognize that cannabis product variability, individual differences in endocannabinoid metabolism, and the biphasic dose-response relationship observed in preclinical studies mean that empiric titration remains essential and that “more” cannabis does not necessarily equate to better pain control. Additionally, the interplay between exogenous cannabinoids and intrinsic endocannabinoid 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Role%20of%20Concentration%20in%20Opposing%20Effects%20of%20Anandamide%20on%20Nociceptive%20Synapses%20versus%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72832)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72832)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Role%20of%20Concentration%20in%20Opposing%20Effects%20of%20Anandamide%20on%20Nociceptive%20Synapses%20versus%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72832)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://pmc.ncbi.nlm.nih.gov/articles/PMC13159970/](https://pmc.ncbi.nlm.nih.gov/articles/PMC13159970/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).